RESUMEN
OBJECTIVE: To assess the effects of pre-existing malnutrition on the treatment outcome of children with acute lymphoblastic leukaemia. METHODS: One hundred and sixty three patients with Acute Lymphoblastic Leukaemia (ALL) below the age of 14 years with L1 and L2 FAB morphology were included in this study. Treatment protocol used was FBM. Patients were classified according to Waterlow classifications of malnutrition (1976). Group-I, as Under-Nourished children (UNC) and Group-II as Well-nourished children (WNC). Percentages in both groups were calculated with respect to total expired, relapses and completed treatment. RESULTS: In Group-I (UNC) 46% completed treatment and were alive, 9.8% relapsed and 45% expired. In Group-II (WNC) 59% completed treatment and were alive, 21.3% relapsed and 19% expired. Overall, in WNC group 13.5% completed treatment and were alive, 8% relapsed and 7.3% expired. In UNC group 28.8% completed treatment and were alive, 6% relapsed and 27% expired. CONCLUSION: Pre-Existing malnutrition adversely effects the treatment outcome in children with Acute Lymphoblastic Leukaemia (ALL).
Asunto(s)
Protocolos de Quimioterapia Combinada Antineoplásica , Desnutrición/complicaciones , Leucemia-Linfoma Linfoblástico de Células Precursoras/tratamiento farmacológico , Resultado del Tratamiento , Enfermedad Aguda , Adolescente , Niño , Preescolar , Humanos , Lactante , Recién Nacido , Leucemia-Linfoma Linfoblástico de Células Precursoras/complicaciones , Leucemia-Linfoma Linfoblástico de Células Precursoras/mortalidad , Estudios Prospectivos , Medición de Riesgo , Factores de TiempoRESUMEN
BACKGROUND: Malnutrition is prevalent on large scale in hospitalized patients which increases morbidity and mortality, reduces the effectiveness of medical treatment in our hospitals and impairs the quality of life significantly. Early diagnosis and treatment of malnutrition is gaining the significance day by day. METHODS: A prospective study was carried out to assess the effects of hypoproteinemia malnutrition on the treatment outcome of children with acute lymphoblastic leukemia. One hundred and sixty three patients with Acute Lymphoblastic Leukemia (ALL) below the age of 14 years with L1 and L2 FAB morphology were included in this study. Treatment protocol used was FBM. Patients were classified according to Waterlow classifications of malnutrition (1976). Group-I, as Well-Nourished children (WNC) and Group-II as Mal-nourished children (MNC). Percentages in both groups were found out with respect to total expired, Relapses and completed treatment. RESULTS: In Group-I (WNC) 50 (81.96%) completed treatment and alive, 5 (8.19%) relapsed and 6 (9.8%) expired. In Group-II (MNC) 31(30.39%) completed treatment and alive,8 (7.84%) relapsed and 63 (61.76%) expired. Overall, in WNC group-I 50(30.67%) completed treatment and alive, 5 (3.07%) relapsed and 6(3.68%) expired. In MNC group-II 31 (19.02%) completed treatment and alive, 8 (4.91%) relapsed and 63 (38.65 %) expired. CONCLUSION: Hypoproteinemia affects treatment outcome in children with acute Lymphoblastic
Asunto(s)
Hipoproteinemia/complicaciones , Leucemia-Linfoma Linfoblástico de Células Precursoras/terapia , Adolescente , Niño , Femenino , Humanos , Masculino , Estado Nutricional , Pronóstico , Estudios Prospectivos , Recurrencia , Resultado del TratamientoRESUMEN
Capecitabine is an oral chemotherapeutic agent converted to 5 fluorouracil (5-FU). Neurotoxicity associated with the medication encompasses both central and peripheral nervous systems. We describe a 60 year old man with colonic carcinoma who developed diplopia due to a sixth nerve palsy following the use of capecitabine which is an orally administered prodrug of 5-FU. An MRI of brain did not reveal a space occupying lesion or vascular insult to account for his cranial nerve palsy. The sixth nerve palsy resolved spontaneously once capecitabine was withdrawn. Physicians in all walks of life are increasingly likely to come across such patients and should familiarize themselves with toxicities consequent to chemotherapy. Further research is needed to elucidate the cause of capecitabine associated neurotoxicity.